- IOL Chemicals & Pharmaceuticals received EDQM CEP approval for Clopidogrel Besilate, strengthening access to regulated European markets. It has huge reserves of Rs.1693 cr. vs equity of Rs.59 cr. and reported PAT of Rs.84.48 cr. in 9MFY26 with 50% interim dividend. The company is expanding API presence with REACH registration, new Minoxidil unit, Paracetamol expansion & Rs.150–200 cr. capex plans. Medium-term growth visibility remains strong with export expansion & margin improvement. Stock may surpass its high of Rs.179.
- Lehar Footwears is setting up a new footwear manufacturing unit at Kundli, Haryana focused on sports shoes & EVA footwear. Existing capacity of ~1 lakh pairs/month operates at 85–90% utilisation while phased expansion of 5 lakh pairs/month is planned with capex of up to Rs.25 cr. funded through internal accruals. Expansion into athleisure segment supports long-term growth visibility. Board meeting for results & dividend on 22-5-2026.
- PNC Infratech emerged as L1 bidder for construction of a 4-Lane major bridge over River Ganga on EPC mode with project value of Rs.571.81 cr. in JV with SPS Constructions India. Just keep on radar.
- VA Tech Wabag announced development of its first Bio-CNG plant in Ghaziabad, Uttar Pradesh under its waste-to-energy initiative targeting establishment of 100 Bio-CNG plants across India & global markets. Just keep on radar.
- HFCL to set up Rs.230 cr. defence manufacturing facility in Andhra Pradesh for Multi-Mode Hand Grenades & related products with planned capacity of ~40 lakh units by December 2027. Expansion driven by defence import substitution & rising global defence spending. Keep on track.
- Debt-free, dividend-paying Black Rose has reserves of Rs.164.34 cr. v/s equity of Rs.5 cr. Q4FY26 PAT jumped 114% Q-o-Q to Rs.9.42 cr., while FY26 PAT stood at Rs.22.44 cr. Company announced 125% dividend. New capacity and amines venture with Japanese partners provide strong earnings visibility. Stock looks attractive at Rs.96 v/s life-time high of Rs.239.
- Hester Biosciences reported 974% higher Q4FY26 PAT at Rs.165.46 cr. and raised dividend to 110% from 70% in FY25. Capacity expansion, export growth and H9N2 vaccine commercialisation provide strong long-term visibility. Stock looks attractive at Rs.1834 and may surpass its 52-week high of Rs.2347.
